Under what circumstances should erlotinib be adjusted or discontinued?

The patient's specific condition, drug response, and physician recommendations need to be considered in the decision-making process to adjust or discontinue erlotinib.

If disease progression, that is, tumor growth or spread, is detected through periodic imaging evaluations, erlotinib may no longer be effective enough. At this point, your doctor may recommend stopping erlotinib and consider switching to other effective treatments.

Common toxic effects of erlotinib include rash and diarrhea. In general, these symptoms may gradually become tolerated over time. However, if symptoms are severe enough that the patient cannot tolerate them, such as severe diarrhea that may lead to infection in cancer patients, the dose of erlotinib may need to be reduced or treatment may need to be temporarily discontinued.

Although the incidence is low, erlotinib can cause interstitial pneumonitis, a serious side effect. Once symptoms of interstitial pneumonia occur, such as dyspnea, cough and fever, erlotinib should be discontinued immediately and seek medical attention promptly.

In patients with hepatic failure, the metabolism and excretion of erlotinib may be affected, increasing the risk of drug accumulation in the body. Therefore, use of erlotinib should be discontinued in this situation.

If the pre-treatment examination is normal, if total bilirubin rises to more than 3 times the upper limit of normal, or if transaminases rise to more than 5 times the upper limit of normal, erlotinib treatment may need to be interrupted or stopped.

If the patient concurrently uses strong CYP3A4 inhibitors, such as certain antibiotics, antifungal drugs, etc., the metabolism of erlotinib may be affected, resulting in an increase in drug concentration and an increased risk of adverse reactions. In this case, your doctor may recommend reducing the dose of erlotinib.